SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

UPTRAVI

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (marketed)
Time to market
Already on the market, FDA approved oral tablets December 21, 2015, and the IV formulation July 30, 2021; pediatric (2+) labeling added later.
Why 3/10
No hard, dated binary catalyst in the next ~12 months: UPTRAVI is already approved and commercializing (last FDA action was a supplemental labeling approval on 2026-05-23), and as one small product inside a mega-cap portfolio it is not a share-price driver for JNJ.
Actionable Insight NEUTRAL

Do not trade JNJ on Uptravi: it is a mature, approved product with no pending regulatory decision and it is immaterial to a ~$262 stock (mean analyst target $272.50 implies only ~7% upside, driven by JNJ's broader pipeline). Treat Uptravi as steady franchise revenue, the meaningful stock drivers are JNJ's oncology/immunology and medtech programs, not PAH.

Price Chart

Loading chart...

Executive Summary

UPTRAVI (selexipag), sold by Johnson & Johnson through its Actelion/Janssen unit, is an approved oral (and IV) treatment for pulmonary arterial hypertension, high blood pressure in the lung arteries. The FDA approved it December 21, 2015 after the Phase 3 GRIPHON trial (1,156 patients) showed it cut the risk of disease-progression or hospitalization events by roughly 40% versus placebo, and an IV version was approved July 30, 2021 for patients temporarily unable to take pills. It is a mature commercial product in a competitive niche market and a very small part of a mega-cap company, so it carries no near-term regulatory binary for JNJ stock.

How It Works

Selexipag is a pill (and an IV infusion) that mimics a natural blood-vessel-signaling molecule, prostacyclin, by activating "IP receptors" on the walls of lung arteries. That signal relaxes and widens the arteries, lowering the high blood pressure in the lungs that defines pulmonary arterial hypertension (PAH). The body converts the pill into an active form that does the receptor work.

Trial Status

Approved on the strength of the Phase 3 GRIPHON study (1,156 patients with symptomatic PAH), which showed a ~40% reduction in risk of a morbidity/mortality event vs placebo; an IV formulation was approved in 2021; the label now covers adults and children 2+; a supplemental FDA action (labeling, POWDER) was recorded 2026-05-23. A small Phase 2 study of selexipag in Raynaud's phenomenon (Actelion, NCT02260557, n=74) completed without posted results.

The Two-Sided Case

▲ Bull Case4
Proven efficacy: GRIPHON Phase 3 (1,156 patients) showed UPTRAVI reduced the risk of a morbidity/mortality event by 40% vs placebo (J&J Medical Connect; FDA label).
Broad label: approved for adults and children 2+, in oral and IV forms, with a marketing claim of ten years of safety data, the longest follow-up of any PAH therapy (uptravi.com; DailyMed).
Continued franchise upkeep: a supplemental FDA approval action (labeling) was recorded as recently as May 23, 2026, showing the product remains actively maintained.
Zero binary risk to the parent: JNJ is a diversified mega-cap at $262.37 with 22 analysts covering it (mean price target $272.50), so this one drug cannot move the stock.
▼ Bear Case4
No catalyst: as an approved, marketed drug with only labeling-level FDA activity, Uptravi offers no near-term PDUFA/pivotal readout to trade, commercial growth is gradual, not binary.
Immateriality cuts both ways: Uptravi is absent from JNJ's recent FDA catalyst slate (IMAAVY, RYBREVANT, CAPLYTA, TECNIS etc. dominate), so even good news here barely registers in a stock that is up ~54% over 12 months on other drivers.
Competitive, niche market: PAH has multiple approved therapy classes, and Uptravi, approved in 2015, faces ongoing competition and eventual generic/loss-of-exclusivity pressure typical of an oral small molecule (approval history via FDA Drug Trials Snapshots).
Stock-level setup is mixed: JNJ's 30-day local bull/bear checklist is net bearish (insider sales including the CEO, ~55-62% daily short-volume ratio), though driven by company-wide factors, not this drug.

Upcoming Catalysts

  • No scheduled regulatory binary for Uptravi in the next ~12 months; watch JNJ quarterly earnings for the Uptravi sales line
  • Any generic/selexipag entry or patent-expiry news would be the main long-term commercial event
  • Minor: results status of the completed Phase 2 Raynaud's study (NCT02260557), which has no commercial bearing on PAH

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 11

Hover a chip for the title
1 jnj.com2 fda.gov3 accessdata.fda.gov4 jnjmedicalconnect.com5 en.wikipedia.org6 uptravi.com7 dailymed.nlm.nih.gov8 secure.medicalletter.org9 drugs.com10 uptravihcp.com11 jnjwithme.com